-+ 0.00%
-+ 0.00%
-+ 0.00%

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

Barchart·08/05/2026 06:00:00
Listen to the news

– Topline data from LUGANO pivotal Phase 3 wet AMD clinical trial expected in August 2026 ––

– Topline data from LUCIA pivotal Phase 3 wet AMD clinical trial anticipated in Q4 2026 ––

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.